<div id="readability-page-1"><p>Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned an average rating of &#34;Moderate Buy&#34; from the five brokerages that are  covering the stock, MarketBeat Ratings reports. One equities research analyst  has rated the stock with a sell rating and four have given a buy rating to  the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $13.75.</p><div><p><span></span><span>Get <strong>Corvus Pharmaceuticals</strong> alerts:</span></p></div><p>Several analysts recently issued reports on CRVS shares. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 9th. Barclays began coverage on shares of Corvus Pharmaceuticals in a report on Monday. They set an &#34;overweight&#34; rating and a $16.00 target price on the stock. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th.</p><p><b>Read Our Latest Report on CRVS</b></p><h2>Corvus Pharmaceuticals Trading Down 4.4%</h2><p>Shares of CRVS stock opened at $6.93 on Monday. The company has a market capitalization of $516.35 million, a PE ratio of -6.86 and a beta of 0.57. The firm has a fifty day simple moving average of $5.83 and a 200-day simple moving average of $4.49. Corvus Pharmaceuticals has a twelve month low of $2.54 and a twelve month high of $10.00. </p><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03.  Equities research analysts predict that  Corvus Pharmaceuticals will post -0.63 EPS for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Shelton Wealth Management LLC acquired a new position in  Corvus Pharmaceuticals during the 3rd quarter valued at about $101,000.  China Universal Asset Management Co. Ltd. increased its stake in  Corvus Pharmaceuticals by 20.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company's stock valued at $62,000 after buying an additional 2,599 shares during the period.  Squarepoint Ops LLC increased its stake in  Corvus Pharmaceuticals by 37.0% during the 2nd quarter. Squarepoint Ops LLC now owns 138,462 shares of the company's stock valued at $554,000 after buying an additional 37,430 shares during the period.  Sender Co &amp; Partners Inc. acquired a new position in  Corvus Pharmaceuticals during the 2nd quarter valued at about $52,000.  Finally, Perceptive Advisors LLC acquired a new position in  Corvus Pharmaceuticals during the 2nd quarter valued at about $5,754,000. 46.64% of the stock is owned by institutional investors and hedge funds. </p><h2>About Corvus Pharmaceuticals</h2> (Get Free Report)<p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p><h2>See Also</h2><ul><li>Five stocks we like better than Corvus Pharmaceuticals</li><li>5 discounted opportunities for dividend growth investors</li><li>Is the Reddit-ChatGPT Love Affair Over?</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>3 Copper Stocks Ready to Shine in the Next Metal Supercycle</li><li>Earnings Per Share Calculator: How to Calculate EPS</li><li>Microsoft 365 Premium Marks the Next Phase of AI Monetization</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRVS

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has received an average rating of "Moderate Buy" from five brokerages. One analyst rated it as a sell, while four rated it as a buy. The average price target is $13.75. Recent reports include Barclays setting an "overweight" rating with a $16.00 target, and Weiss Ratings maintaining a "sell" rating. The stock opened at $6.93, with a market cap of $516.35 million. Institutional investors own 46.64% of the stock. Corvus focuses on developing immune modulators for treating various diseases.</p>

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Analysts